<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01794169</url>
  </required_header>
  <id_info>
    <org_study_id>SWEAML12-a</org_study_id>
    <nct_id>NCT01794169</nct_id>
  </id_info>
  <brief_title>Azacitidine Compared to Conventional Chemotherapy as Consolidation of Elderly Patients With AML</brief_title>
  <official_title>Azacitidine Compared to Conventional Chemotherapy in Consolidation of Elderly Patients (65 Years or Older) With AML in First Complete Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Azacitidine consolidation is superior to
      standard DA consolidation treatment of acute myeloid leukemia in first complete remission in
      elderly patients.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor recruitment
  </why_stopped>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Leukemia free survival</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related morbidity and mortality</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe Adverse Events (SAE)</measure>
    <time_frame>Two months after the last course of consolidation</time_frame>
    <description>SAE as defined by CTCAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days admitted in hospital</measure>
    <time_frame>12 months from start of consolidation treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Until 24 months from start of consolidation treatment</time_frame>
    <description>EORTC QLQ C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with AE grade 3 or more</measure>
    <time_frame>Until two months after the last course of consolidation</time_frame>
    <description>AE:s graded according to CTCAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of consolidation courses actually given within the study</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Molecular analyses</measure>
    <time_frame>Two years</time_frame>
    <description>Analysis of a broad spectrum of molecular and cellular events relating to the epigenetic status of the malignant cells. These events will be used to identify biomarkers for successful consolidation and to address whether AML cases that relapse while on the study are molecularly and epigenetically different between those given azacitidine or DA consolidation</description>
  </other_outcome>
  <other_outcome>
    <measure>Leukemia free survival (LFS)</measure>
    <time_frame>One year</time_frame>
    <description>Analysis whether cytogenetic and molecular aberrations at diagnosis will predict for better LFS with either Azacitidine or standard DA consolidation.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azacitidine 75mg/m2/d subcutaneously once daily for 5 days given every 5:th week for 8 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two courses of DA in accordance with the Swedish National treatment program (reduced doses):
In case one induction course was given:
First consolidation course: daunorubicin 45 mg/m2 x 1 (iv infusion) day 1-3 and cytarabine 1000 mg/m2 x 2 (iv infusion) day 1-4.
Second consolidation course: daunorubicin 45 mg/m2 x 1( iv infusion) day 1-2 and cytarabine 200 mg x 2 (fixed dose sc injection) day 1- 5.
In case two induction courses were given:
First consolidation course: daunorubicin 45 mg/m2 x 1( iv infusion) day 1-2 and cytarabine 200 mg x 2 (fixed dose sc injection) day 1- 5.
Second consolidation course: cytarabine 200mg x 2 (fixed dose sc injection) day 1-5.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <arm_group_label>Azacitidine</arm_group_label>
    <other_name>Vidaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA</intervention_name>
    <arm_group_label>DA</arm_group_label>
    <other_name>Daunorubicin</other_name>
    <other_name>Cytarabine</other_name>
    <other_name>Ara-C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects &gt;65 years of age at the time of signing the informed consent form

          2. A confirmed diagnosis of AML according to the 2008 WHO classification

               -  This includes: Bone marrow aspirate with a good clot or biopsy for morphology,
                  flow cytometry, cytogenetic analysis, and in case of normal cytogenetics,
                  molecular genetic analyses including FLT3-ITD, NPM-1 and CEBP A

               -  Bio-banking of leukemic cells at diagnosis performed (according to guidelines of
                  the Swedish National AML biobank).

          3. A documented CR or CRp achieved after one or two induction courses.

        Exclusion Criteria:

          1. Subjects who are not considered to be candidates to complete the consolidation therapy
             due to medical or psychological reasons.

          2. Subjects who have taken any investigational drugs or participated in an interventional
             clinical trial within 30 days prior to screening.

          3. Patients with acute promyelocytic leukemia

          4. Patients with t(8;21) or inv(16)

          5. CNS leukemia

          6. Patients with a previous diagnosis of MDS, i.e. AML preceded by a diagnosed MDS

          7. Subjects who are candidates for allogeneic stem cell transplantation (SCT)

          8. Another cancer diagnosis with a life expectancy of less than two years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Bernell, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefan Deneberg, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karolinska University Hospital, Solna</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2013</study_first_submitted>
  <study_first_submitted_qc>February 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2013</study_first_posted>
  <last_update_submitted>September 19, 2015</last_update_submitted>
  <last_update_submitted_qc>September 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Stefan Deneberg</investigator_full_name>
    <investigator_title>M.D, Ph.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

